20 May 2013
Keywords: results, novelos, ph, iii, ncslc, trial, expected
Article | 24 March 2008
Novelos Therapeutics, a US biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, has reached
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 March 2008
17 March 2008
17 May 2013
© 2013 thepharmaletter.com